Beyond Longevity

Beyond Longevity

Download on the App Store

Beyond Longevity episodes

  • Beyond Longevity at HLTH Europe Part Two: Microbiomes, Breath Diagnostics and the Future of Medical AI

    Recorded at HLTH Europe in Amsterdam, Part Two of our special series looks at four very different ways technology could help healthcare move earlier, become more personalised and make better use of the growing amount of health data we are collecting.

    Dr Marta Ciechonska, Co-Founder and CEO of Salient Bio, explores what the microbes living in our gut, mouth and vaginal microbiome can tell us about health. She explains how metagenomic testing and machine learning are being used to move microbiome science towards clinical diagnostics, including work in inflammatory bowel disease, as well as the links between oral health, systemic inflammation and changes associated with menopause.

    Ilay Marom, Co-Founder and COO of NaNose Medical, introduces a very different approach to early detection: analysing biomarkers in our breath. He explains how nanosensors and AI can identify patterns associated with diseases including lung cancer and advanced liver fibrosis, what the technology is actually measuring, how accurate it could become and whether breath testing could eventually make large-scale screening more accessible and affordable.

    Aad R. Liefveld, Chief Growth Officer at PACE Clinical, tackles a problem that has little to do with discovering new treatments and everything to do with whether patients actually follow them. We discuss why people struggle with adherence, how behavioural modelling can identify patients at risk of dropping out or deviating from treatment protocols, and why poor adherence can distort the results of clinical trials themselves.

    Finally, Ruth Prieto of Nebius takes us behind the scenes of medical AI. We discuss the computing infrastructure required to power increasingly complex healthcare applications, from drug discovery to diagnostics, alongside the questions around privacy, security, regulation and what meaningful AI adoption in healthcare actually looks like.

    Together, the conversations raise a broader question running through much of HLTH Europe: can we use technology not simply to collect more health data, but to detect problems earlier, intervene more intelligently and ultimately keep people healthier for longer?

    Marta Ciechonska - Salient Bio

    https://www.linkedin.com/in/marta-ciechonska/

    Salient Bio

    Ilay Marom - Co-Founder & COO at Nanose Medical

    https://www.linkedin.com/in/ilay-marom-846793218/

    Nanose Medical - Nanose -Disease diagnosis - Official Website

    Adriaan Rudolf (Aad) Liefveld -

    https://www.linkedin.com/in/liefveld/

    https://www.paceclinical.com/

    Ruth Prieto - Communications Manager and External Communications PR lead at Nebius

    https://www.linkedin.com/in/ruth-prieto/

    The Ultimate AI Cloud

    Find out about HLTH Europe https://hlth.com/events/europe/ See you there next year

    Running order

    00:00 Back at HLTH Europe

    01:49 Microbiome Diagnostics

    05:24 From Testing to Prevention

    08:28 Breath Biomarkers for Earlier Detection

    11:18 How Breath Sensing Works

    15:50 Accuracy, Cost and Accessibility

    18:05 Scaling Preventive Diagnostics

    23:30 Why Patients Struggle With Adherence

    28:50 The Behaviour Behind Non-Adherence

    30:14 B-COMPASS and Proactive Support

    31:08 The Clinical Trial Dropout Problem

    32:03 How Protocol Deviations Distort Data

    34:16 Rethinking Clinical Trials and R&D

    37:56 Who Should Pay for Better Adherence?

    40:46 Making Health Technology Accessible as We Age

    42:37 The Infrastructure Behind Medical AI

    46:37 How AI Is Changing Drug Discovery

    47:41 Privacy, Security and Real-World AI

    49:58 Breakthrough Projects and Recognition

    55:33 Closing Reflections

    58 min
  • Beyond Longevity at HLTH Europe: Wearables, AI and Remote Rehabilitation for Preventive Health

    What happens when technology stops simply tracking our health and starts helping us understand what to do about it?

    Recorded at HLTH Europe in Amsterdam, this episode of Beyond Longevity features three conversations with founders working across very different areas of health technology. From understanding our individual stress response and making sense of an overwhelming amount of health data, to bringing rehabilitation into the home, these conversations explore what preventive health could actually look like in practice.

    Timothée Manschot, Founder and CEO of NOWATCH, is rethinking what a health wearable should do. NOWATCH continuously measures signals including electrodermal activity to understand how an individual’s body responds to stress and builds a personalised baseline over time. We discuss what Timothée calls “compassionate technology”, why more health data isn’t necessarily better, and NOWATCH’s unusual approach to privacy, where users remain in control of their own data.

    https://www.linkedin.com/in/timmanschot/

    Nowatch - Polsen Health | Screenless Health Tracker for Stress, Sleep, Activity & Recovery

    Samir Mitra, Founder and CEO of REYA.AI, has spent decades at the forefront of technology. He was part of the original Java team at Sun Microsystems and later became an Entrepreneur-in-Residence at Sequoia Capital. Today, he’s applying that experience to longevity medicine. REYA.AI helps clinicians bring together medical records, blood tests, genetics, wearables and other health data, using AI to identify what actually matters. We discuss where AI can outperform humans, where it can’t, and why Samir believes clinical judgement and context still need to remain at the centre of healthcare.

    https://www.linkedin.com/in/samir-mitra-1623164/

    Reya Ai

    Roy Shteren, CEO and Co-Founder of WizeCare Technologies, is tackling another major challenge: how to make rehabilitation available to more people without requiring every session to happen face-to-face. WizeCare uses AI and movement tracking to support remote physiotherapy without additional hardware. We explore how the same technology could go beyond recovery and help identify changes in movement, mobility and fall risk before they become a bigger problem.

    https://www.linkedin.com/in/roy-shteren/

    https://www.wizecare.com/

    Find out more about HLTH Europe:

    https://hlth.com/events/europe/

    See you there next year.

    Next week:

    Part Two from HLTH Europe, where we explore the microbiome, breath-based disease detection, patient adherence and the AI infrastructure behind medical research.

    Timestamps

    00:00 Welcome to HLTH Europe in Amsterdam

    01:04 What We’re Exploring

    02:00 Timothée Manschot and NOWATCH

    04:08 Understanding Your Stress Baseline

    05:25 What Is Compassionate Technology?

    08:13 A Privacy-First Approach to Health Data

    15:22 Wearables, Health and Longevity

    17:29 Samir Mitra and REYA.AI

    21:32 How AI Can Help Clinicians

    23:17 Why Human Judgement Still Matters

    29:01 Where Could Healthcare AI Be in 10 Years?

    33:16 Roy Shteren and WizeCare

    36:51 From Rehabilitation to Prevention

    38:59 Can Remote Rehabilitation Scale?

    41:17 Final Thoughts and Part Two

    43 min
  • Can a Senolytic Vaccine Slow Ageing? Dr David Scieszka on Senescent Cells and Longevity

    What if a vaccine could help the immune system clear senescent “zombie” cells — damaged cells linked to ageing, chronic inflammation and age-related disease?

    In this episode of Beyond Longevity, Daphna Stern sits down with David Scieszka, PhD, MBA, a biomedical scientist, computational biologist, and Founder and CEO of Vertical Longevity Pharmaceuticals (VeLo Pharma). His route into longevity has been anything but conventional, spanning service in the US Army, wet-lab science, computational biology and, eventually, biotech entrepreneurship.

    VeLo Pharma is developing a senolytic vaccine designed to help the immune system recognise and remove senescent cells. Often described as “zombie cells”, these are damaged cells that have stopped dividing but remain active. As they accumulate with age, they can contribute to chronic inflammation, tissue dysfunction and age-related disease.

    The company’s first focus is atherosclerosis, where plaque builds up inside the arteries. The aim is to target senescent cells within the vasculature — the network of blood vessels that carries blood around the body — as a potential new way of tackling vascular ageing and cardiovascular disease.

    But this conversation goes far beyond one experimental vaccine.

    David and Daphna explore one of the biggest problems in longevity science: why so many promising discoveries look exciting in the lab, yet so few make the difficult journey into treatments that patients can actually use.

    They discuss where artificial intelligence can genuinely help drug development — and where the hype may run ahead of the science — what animal and primate studies can and cannot tell us, and what evidence would be needed before an approach like this could move towards human trials.

    David also talks candidly about the business of building a biotech company: learning how to approach investors, getting the fundraising ask wrong, understanding what investors actually need to see, and building a company around a mission that goes beyond simply creating another expensive longevity treatment.

    Running through the conversation is an even bigger question: if we do find effective ways to slow parts of the ageing process, who gets access to them first? Will longevity medicine remain something available primarily to those who can afford it — or can longevity eventually become something for everyone?

    Guest

    David Scieszka, PhD, MBA

    Biomedical scientist, computational biologist, and Founder and CEO

    Vertical Longevity Pharmaceuticals (Velo Pharma)

    Vertical Longevity Pharmaceuticals

    LinkedIn - Vertical Longevity Pharmaceuticals

    Reach out to David on LinkedIn to find out about the upcoming “Ask VeLo Pharma Anything”

    00:00 Welcome and Big Question

    00:25 Meet David Cheska

    02:53 Army Roots of Longevity

    04:38 Choosing Biotech Path

    05:49 Wet Lab Meets Computation

    08:48 AI Promise and Limits

    13:19 Longevity for All Mission

    16:54 Vascular Ageing Explained

    19:29 Senescent Cells 101

    22:31 Lytic Vaccine Overview

    24:11 Dosing and Study Strategy

    26:12 How VLP Vaccines Work

    29:02 Safety and Public Trust

    29:58 Vaccine Safety Basics

    31:14 Senescent Cells Strategy

    32:42 Evidence So Far

    35:35 Primate Trial Goals

    36:40 Why Translation Fails

    39:55 Personalised Longevity Care

    42:41 PhD MBA Path

    44:51 Fundraising Lessons

    49:35 Mission-Driven Team

    51:32 Longevity Next Decade

    53:16 Rapid Fire Wrap

    55:17 Final Takeaways

    57 min
  • Can One Drug Slow Ageing Across the Whole Body? LinkGevity’s Bid to Block Necrosis

    What if heart disease, kidney disease and dementia share a common mechanism linked to ageing? And what if blocking a destructive form of cell death called necrosis could help protect several organs at once?

    In this episode, host Daphna Stern speaks with LinkGevity founders Dr Carina Kern and Serena Kern-Libera about their attempt to develop a new longevity drug targeting necrosis, ageing and age-related disease.

    Their work challenges the conventional model of drug discovery. Medicine generally treats kidney disease, cardiovascular disease and dementia as separate conditions. LinkGevity is asking whether targeting biology shared across these diseases could protect several organs and systems at once.

    At the centre of that approach is necrosis: a destructive form of cell death that can spread damage through surrounding tissue. LinkGevity’s lead candidate, Anti-Necrotic™️, is designed to protect cells from the calcium overload that drives this process. The company is preparing for clinical trials in kidney disease, while investigating whether the same mechanism could eventually have wider applications across ageing, organ preservation and tissue engineering.

    The work has received support from Innovate UK, Horizon Europe, the Francis Crick Institute and the UK Space Agency. LinkGevity was also selected as one of 12 companies for the SPACE-H accelerator, run in collaboration with NASA’s Human Research Program, TRISH and Microsoft Federal.

    The conversation explores the Blueprint Theory of Ageing, the limitations of treating age-related diseases one at a time, and why the kidney may provide a practical first route into human trials. It also examines what the existing laboratory evidence can—and cannot yet—tell us, what would disprove the company’s theory, and how LinkGevity is trying to separate scientific ambition from longevity hype.

    Dr Carina Kern is the founder and CEO of LinkGevity, an AI-enabled biotech company developing treatments for ageing and the loss of biological resilience. A geneticist and ageing researcher, she is the architect of the Blueprint Theory of Ageing, an integrative framework connecting evolutionary principles, genetic pathways, molecular mechanisms and clinical medicine. The theory underpins LinkGevity’s AI-driven drug-discovery platform.

    Serena Kern-Libera is co-founder, Chief Operating Officer and General Counsel of LinkGevity. Before founding the company with her sister, she worked at Magic Circle law firm Slaughter and May, the Bank of England and HM Treasury, and served as Private Secretary to the Chancellor of the Exchequer.

    Together, they lead a multidisciplinary team based at the Babraham Research Campus in Cambridge. Their lead programme is initially targeting kidney disease, but its larger ambition is to test whether blocking necrosis could help protect the body against several forms of age-related degeneration.

    You can find out more here:

    LinkGevity: www.linkgevity.com

    LinkedIn: https://www.linkedin.com/company/linkgevity/

    X: @CarinaCarlaKern

    Research papers:

    https://www.nature.com/articles/s41388…

    https://www.preprints.org/manuscript/202310.1387

    Timestamps

    * 00:00 — Introducing Dr Carina Kern, Serena Kern-Libera and LinkGevity

    * 02:30 — The family story behind the company

    * 05:40 — Lifespan, healthspan and the fear of prolonged ill health

    * 07:30 — Early C. elegans research and publishing findings that challenged convention

    * 11:00 — From academic research to building a company at Babraham

    * 13:15 — The Blueprint Theory of Ageing and the case for systems-level medicine

    * 17:00 — Can ageing be defined and measured well enough to regulate?

    * 21:30 — What GLP-1 drugs reveal about system-level treatments

    * 25:00 — Should kidney disease, heart disease and dementia be treated separately?

    * 27:45 — What the hallmarks of ageing explain—and what they may miss

    * 31:00 — What would disprove the Blueprint Theory?

    * 33:20 — Necrosis and apoptosis: two very different forms of cell death

    * 37:00 — How necrosis can spread tissue damage

    * 41:00 — Calcium overload and how Anti-Necrotic™️ is designed to work

    * 45:00 — The laboratory evidence so far

    * 48:30 — Why necrosis remains a barrier to growing organs in the lab

    * 52:00 — The route to human trials, beginning with kidney disease

    * 55:00 — NASA, the UK Space Agency and “cosmic kidneys”

    * 59:00 — Working with the NHS and the case for a gateway trial

    * 1:02:30 — Longevity hype, scientific rigour and the risks of the label

    * 1:06:00 — Is society prepared for a genuine breakthrough in healthspan?

    * 1:09:00 — What each sister is most afraid of getting wrong

    * 1:11:00 — Rapid-fire five questions

    * 1:14:00 — Closing reflections and host takeaway

    1 hr 7 min
  • How Much Control Do We Really Have Over Our Health? Spermidine, Autophagy and Patient Empowerment

    At 39, Leslie Kenny was diagnosed with rheumatoid arthritis and lupus and says she was told she had around five years to live. More than two decades later, she is in long-term remission and has turned that experience into a mission: helping patients become better informed, more involved and more confident in decisions about their own health.

    In this episode, Leslie Kenny, founder of Oxford Healthspan and co-founder of the Oxford Longevity Project, joins Daphna Stern to tell the story of how she challenged her original prognosis, found intravenous immunoglobulin (IVIG) through her own research, changed her diet and ultimately reached remission.

    But her story also raises a much bigger question: where should patient empowerment end and medical expertise begin?

    The conversation then turns to spermidine, a naturally occurring compound found in the body and in foods that has attracted growing interest for its relationship with autophagy — the cellular recycling process that helps remove and reuse damaged cellular material. Leslie explains why she became convinced of its potential and why she believes natural compounds such as spermidine struggle to attract the research funding available to patentable drugs.

    Daphna also pushes on the evidence. How much do we actually know about spermidine in humans? What can observational studies tell us — and what can they not? How does the evidence compare with interventions such as rapamycin? And when does an intriguing longevity molecule become something we can genuinely recommend?

    The conversation expands beyond supplements into a broader discussion about personal responsibility for health, the exposome, the future of preventative medicine and what healthcare could look like if it focused not simply on extending life, but on helping people live well for longer — right through to the end.

    Guest Bio

    Leslie Kenny is the founder of Oxford Healthspan and co-founder of the Oxford Longevity Project. Diagnosed with rheumatoid arthritis and lupus at 39 and given a five-year prognosis, Kenny used patient research, dietary overhaul, and an experimental immunoglobulin therapy to reverse her condition into long-term remission. She trained at the Institute for Integrative Nutrition and now serves as Global Executive Ambassador for the Japan Autophagy Consortium. Through Oxford Healthspan, she develops food-derived spermidine and nettle-based nutraceuticals, and through the Oxford Longevity Project, she works alongside scientists including Sir Muir Gray, Sir Christopher Ball, Dr Paul Chen, and Emeritus Professor Dennis Noble to advance patient-centred ageing research.

    LinkedIn: https://www.linkedin.com/in/leslie-kenny-oxford/

    Timestamps

    * 00:00 — Introduction to Leslie Kenny and her story

    * 02:10 — IVF, autoimmune disease and the diagnosis that changed everything

    * 04:30 — Questioning the original diagnosis and discovering a thyroid problem

    * 08:15 — How patient research led Leslie to intravenous immunoglobulin (IVIG)

    * 13:00 — Diet, elimination protocols and visualisation

    * 17:40 — Reaching remission and turning personal experience into advocacy

    * 21:50 — How to challenge your doctor without rejecting conventional medicine

    * 25:30 — What spermidine is and why Leslie became interested in it

    * 29:15 — Spermidine, the hallmarks of ageing and the comparison with rapamycin

    * 34:00 — Why natural compounds can struggle for funding, patents and attention

    * 38:20 — What the human evidence for spermidine actually tells us

    * 43:10 — The funding problem in independent longevity research

    * 45:30 — Oxford Healthspan and the Oxford Longevity Project

    * 48:00 — How much control do we really have over our health and ageing?

    * 52:00 — Rethinking hospitals, later life and what a good death looks like

    * 56:30 — Rapid-fire questions

    * 59:00 — Closing reflections

    References & Further Reading

    • Kenny, L. — founder, Oxford Healthspan
    • Oxford Longevity Project (co-founded with Sir Muir Gray, Sir Christopher Ball, Dr. Paul Chen, Prof. Dennis Noble)
    • Sears, B. — The Anti-Aging Zone
    • Franceschi, C. — originator of the "inflammaging" concept
    • Partridge, L., Madeo, F., Kennedy, B. — research on spermidine and the hallmarks of ageing
    • Eisenberg, T., et al. — Grazer study on spermidine and human cell telomeres (2021)

    1 hr
  • The Hardest Problem in Longevity Is Human Behaviour with Dr Gil Blander, Founder of InsideTracker

    Nearly two decades ago, Dr Gil Blander was trying to convince investors of an idea that, at the time, sounded radical: blood biomarkers should not only be used to diagnose disease, but to help healthy people understand what to change before disease develops.

    Some thought he was crazy.

    That idea became InsideTracker, the company he founded 17 years ago, which brings together blood biomarkers, genetic information and wearable data to give people personalised recommendations for improving their health.

    In this conversation, Dr Blander traces the scientific journey that took him from the Weizmann Institute to MIT and eventually to founding InsideTracker. He explains what he learned from some of the early breakthroughs in longevity research, why collecting more health data is not enough if people do not act on it, and why he believes behaviour change may now be one of the biggest challenges in extending healthy life.

    We also discuss his recent decision to step back from his operational role at InsideTracker and what he describes as his “second career”: taking personalised, preventative health beyond the longevity community and making it relevant to a much wider population.

    Guest Bio

    Dr Gil Blander is the founder of InsideTracker, a personalised health and longevity platform that combines blood biomarkers, DNA and wearable data to generate individualised health recommendations.

    He trained as a scientist at the Weizmann Institute, where he worked with Professor Moshe Oren on p53 and cancer biology, before moving to MIT to join Professor Leonard Guarente’s laboratory during an important period in the study of genes associated with ageing and longevity.

    After 17 years leading InsideTracker, Dr Blander recently stepped back from his operational role to focus on bringing personalised and preventative health to a much broader population.

    About Dr Gil Blander

    Principal: Healthspan Strategies Advisors and Founder and CEO of Stealth Health Tech startup

    * Instagram: Founder of @insidetracker

    * Instagram: Host of @beyond_healthspan_podcast

    * LinkedIn: linkedin.com/in/gilblander

    * Company: insidetracker.com

    * Longevity by Design: info.insidetracker.com/longevitybydesign

    Episode Chapters

    * 00:00 Welcome and Guest Introduction

    * 03:07 Why Data Alone Does Not Change Health

    * 05:02 Different People Need Different Motivation

    * 07:01 The Scientific Roots at Weizmann

    * 11:50 Inside MIT’s Early Longevity Research

    * 13:24 Leaving Academia for Industry

    * 16:04 The Idea Behind InsideTracker

    * 19:25 How InsideTracker Works

    * 20:35 Why Blood, DNA and Wearables Work Better Together

    * 26:14 Why Behaviour Change May Be the Real Frontier

    * 27:48 Taking Longevity Beyond the Longevity Bubble

    * 30:43 What Actually Makes Healthy Habits Stick

    * 34:58 What Real-World Data Can Teach Us

    * 40:29 Stepping Back and Starting a “Second Career”

    * 42:05 Longevity Hype, Science and the Limits of What We Know

    * 44:27 Rapid Fire

    * 47:20 Final Takeaways

    49 min
  • Longevity Medicine Beyond ‘Failure-Based’ Healthcare with Dr Peter Scriven

    In this episode of Beyond Longevity, Daphna speaks with Dr Peter Scriven, Co-Founder and Clinical & Scientific Director of LONGEVITY, about what longevity medicine should actually look like: moving from reactive, disease-led healthcare towards preventative, personalised medicine that tracks biomarkers, cardiovascular risk and health trajectory over time.

    Dr Peter describes much of conventional healthcare as ‘failure-based medicine’ — a system designed to respond once something has gone wrong. He questions the reliance on population-based ‘normal’ laboratory ranges, which can obscure meaningful changes within an individual, and makes the case for longitudinal ‘human telemetry’: following biomarkers and other health data over time rather than relying on isolated snapshots.

    They discuss what responsible longevity testing should look like, including a core panel of around 50–80 blood biomarkers, more targeted diagnostics according to age, sex, symptoms and individual goals, and the importance of having a clear clinical reason for every test. Dr Peter also explains why more testing is not necessarily better, and why interpretation, clinical oversight and sensible testing intervals matter.

    The conversation examines the realities of longevity medicine and preventative health screening, from several hundred pounds for more focused assessments to several thousand when extensive diagnostics and medical imaging are included, and where he believes people should prioritise their spending.

    Dr Peter explains how his father’s missed cardiovascular risk and inadequate lipid testing helped shape his approach to preventative medicine. He also discusses the largely unregulated ‘Wild West’ of longevity, including peptides and other interventions promoted ahead of strong clinical evidence, and the checks patients can make when assessing a longevity clinic or practitioner.

    And beneath the diagnostics, biological-age testing and emerging technologies, he returns to the foundations of healthspan: movement, nutrition, sleep and purpose.

    For those working with a limited budget, he identifies three areas he believes are worth considering first: a proper cardiovascular risk assessment, omega-3 to omega-6 balance, and GlycanAge testing.

    https://longevityclinics.life/

    https://www.linkedin.com/in/drpscriven/

    00:00 Why Prevention Matters

    03:12 Failure-Based Medicine

    04:34 Human Telemetry Monitoring

    06:28 Testing Without Overtesting

    09:53 Core vs Targeted Panels

    13:13 Cost and ROI of Diagnostics

    17:54 Healthspan Intervention Pyramid

    20:53 Normal Ranges vs Trajectories

    24:36 Missed Risks Real Stories

    28:46 Breaking Medical Silos

    33:49 Renaissance Medic Mindset

    36:05 Training Beyond Silos

    36:49 Regulating Longevity Medicine

    37:43 Patients or Permanent Clients

    41:01 Too Much Testing Ethics

    44:08 Peptides and Amateur Hype

    45:42 How to Vet a Clinic

    49:01 Budget Biomarkers That Matter

    52:13 Foundations and Wearables

    55:19 Future of Cellular Medicine

    58:30 Long-Term Clinic Journey

    01:00:00 Rapid Fire and Wrap Up

    1 hr 3 min
  • Longevity at HLTH Why Healthy Ageing Is Finally Going Mainstream

    In this episode of Beyond Longevity, Daphna speaks with Jody Tropeano Greene, Head of Content at HLTH, and Alexa Mikhail, Senior Content Lead at HLTH US, about how HLTH identifies the healthcare topics that matter most, balances emerging trends with scientific evidence, and reflects the growing importance of longevity within modern healthcare.

    They explore the difference between healthy ageing—grounded in well-established principles such as sleep, nutrition, exercise, stress management and social connection—and the consumer longevity movement, where interventions are often expensive, and the supporting evidence is still evolving.

    The conversation examines the gap between health insights and meaningful behaviour change, asking why biomarker data alone rarely translates into better health outcomes. They also discuss whether healthcare systems and insurers are likely to invest more in preventative healthcare beyond wearables and lifestyle programmes.

    Other topics include the importance of social health and loneliness, the evidence gap in women’s health, why strength should take priority over the pursuit of being “small”, the opportunities and limitations of GLP-1 medicines, longevity’s communication challenge, and how artificial intelligence could reshape primary care and expand access to preventative healthcare. HLTH and Longevity: Healthy Ageing, Evidence and Women’s Health

    Beyond Longevity examines how longevity has moved from a niche topic into mainstream healthcare, using HLTH’s major US and Europe conferences as a bellwether. Host Daphna speaks with HLTH head of content, Jody Tropeano Greene and HLTH US content lead, Alexa Mikhail, about how they build agenda programming that surfaces trending issues while insisting on credible evidence, and why they are dedicating a full day to longevity.

    They distinguish healthy ageing (population-level, researched basics such as sleep, nutrition, movement, stress and relationships) from consumer longevity biohacking (often expensive and sometimes unproven), discuss the “insight–action gap” from biomarker data, and debate whether insurers will fund prevention beyond wearables and lifestyle supports.

    HLTH USA is the premier event taking place November 15-18 in Las Vegas, where leaders from across the healthcare ecosystem come together to share insights, spark inspiration, and shape the global health agenda. Attendees gain a comprehensive view of healthcare advancements, from policy and market dynamics to cutting-edge consumer health technologies - all aimed at improving the well-being of individuals worldwide.

    Register and save $1,000+ by Friday, July 31

    https://hlth.com/

    Jody Tropeano Greene

    Head of Content, HLTH

    https://www.linkedin.com/in/jodytropeano/

    Alexa Mikhail

    Content Lead, HLTH US

    Senior health and longevity writer, SHE Media, Flow Space

    https://www.linkedin.com/in/alexamikhail/

    00:00 Welcome to Beyond Longevity

    00:25 Why HLTH Matters

    01:26 Meet Jody and Alexa

    03:02 How HLTH Picks Topics

    04:41 Healthy Ageing vs Longevity

    07:51 Credibility Over Hype

    09:05 When Trends Go Mainstream

    11:49 Prevention and Insurance

    15:58 Loneliness as Longevity

    17:05 What Makes Startups Break Through

    19:19 Women Left Out of Data

    23:44 Strength Over Smallness

    26:41 Practical Healthspan Habits

    27:45 Elevating Women's Health

    29:19 Building Consumer Wellness

    31:24 Longevity Goes Mainstream

    32:21 Making Basics Profitable

    34:17 Longevity Language Problem

    35:24 Preparedness And Community

    38:45 GLP1 Promise And Risks

    42:13 Healthcare In Ten Years

    45:17 Assumptions To Challenge

    47:22 Rapid Fire And Wrap

    53 min
  • From Blockbuster Medicine to Extending Healthspan with Sundeep Dugar PhD

    On Beyond Longevity, host Daphna speaks with Dr Sundeep Dugar, PhD, co-founder of BlueOakNx and the scientists behind the blockbuster cholesterol medicines Zetia (ezetimibe) and Vytorin. He explains how Zetia transformed cholesterol treatment by blocking cholesterol absorption in the intestine, and reflects on what it really takes to discover a breakthrough medicine: collaboration, perseverance, intellectual honesty, and the willingness to follow the data despite constant uncertainty.

    Dr Sundeep discusses why artificial intelligence is set to transform drug discovery by accelerating analysis and identifying patterns that humans might miss, while arguing that it cannot replace scientific judgment or the need to validate therapies in complex biological systems. He also critiques modern drug development for being overly reductionist, focusing heavily on efficacy while too often overlooking whole-body biology and long-term safety.

    The conversation explores his decision to leave traditional pharmaceutical drug development and focus instead on extending healthspan through BlueOakNx. He explains the science behind mitochondrial health and epicatechin, a naturally occurring compound that promotes mitochondrial biogenesis and energy production, while emphasising that it is designed to complement—not replace—the foundations of good health, including exercise, sleep and nutrition.

    Dr Sundeep also explains why BlueOakNx chose the nutraceutical route, believing it offered the fastest way to make scientifically grounded interventions more accessible, more affordable and available to more people than the conventional pharmaceutical pathway. He discusses the company’s collaboration with the New York Academy of Sciences on a symposium series focused on energy metabolism, and BlueOakNx’s selection as one of just 40 teams chosen from more than 600 applicants to compete in the $101 million XPRIZE Healthspan competition.

    Resources

    * BlueOakNx website

    * Dr Sundeep’s LinkedIn

    * New York Academy of Sciences – Energy Symposium Series

    00:00 Podcast Intro Guest

    02:32 Blockbuster Drugs Legacy

    05:37 How Zetia Was Found

    07:29 Breakthroughs Doubt Lab

    11:46 AI Limits Drug Discovery

    17:47 Why Drug Candidates Fail

    20:52 From Pharma to Ageing

    21:54 Mitochondria Energy Quest

    27:23 Blue Oak Mission Epicatechin

    31:57 Key Terms Next Steps

    32:13 Not a Muscle Pill

    32:59 Mitochondria and Real Exercise

    34:26 Ageing and Energy Decline

    35:26 Supplement Not a Substitute

    37:19 Why Go Nutraceutical

    41:01 Science and Access Model

    43:50 Affordability and Outreach

    46:41 XPRIZE Healthspan Entry

    49:39 Safety First Philosophy

    54:14 Rapid Fire and Wrap Up

    58:06 Host Closing Message

    1 hr
  • Robert Gielow on Longevity Products, Pharmacy Access and Consumer Trust with a focus on the German speaking market

    Daphna sat down with Robert Gielow, founder of Mentry Pharma, to discuss what it really takes for foreign supplement and longevity companies to enter the pharmacy markets of Germany, Austria and Switzerland. He explains why many brands misunderstand the German-speaking market: distribution and pharmacy listings alone do not create demand, pharmacies are not straightforward sales channels, and sceptical consumers require multiple trust-building touchpoints before making a purchase.

    The conversation explores the practical realities of regulation, market access and enforcement, the differences between brick-and-mortar and online pharmacies, and why many market entries fail when companies focus on sales projections rather than customer acquisition and long-term retention. Gielow also discusses the challenges of consumer education, the influence of misinformation on social media, and the widening gap between rigorous scientific evidence and the content that attracts the greatest online attention.

    Finally, he argues that prevention remains undervalued across healthcare systems and that longevity does not have to depend on expensive interventions. Instead, he makes the case for focusing on the fundamentals: regular movement, good nutrition, quality sleep, strong relationships, and learning to listen to the body’s signals.

    https://www.mentry-pharma.com/

    https://www.linkedin.com/in/robertgielow/

    00:00 Welcome and Episode Setup

    02:16 Meet Robert and Mentory Pharma

    04:18 How Mentory Pharma Started

    08:31 Why Distribution Alone Fails

    11:04 Pharmacies Aren't Salespeople

    13:59 Why Brands Fail in Germany

    19:12 Regulation Reality Check

    25:39 Influencers vs Real Science

    28:17 What Even Is Longevity

    28:42 Vitamin D Rules Clash

    31:09 Enforcement Reality Check

    32:49 Why Prevention Lags

    35:39 Pharma Shifts to Prevention

    38:07 Markets Ahead of Europe

    43:25 Longevity for the Rich

    46:08 Back to Simple Habits

    50:34 Building Credible Brands

    55:26 Rapid Fire Takeaways

    57:55 Closing Reflections

    1 hr 1 min

About Beyond Longevity

From the publisher's feed

Beyond Longevity explores the science, medicine, technology, business and policy shaping longer, healthier lives. Host Daphna Stern speaks with leading researchers, clinicians, founders and experts…